Interlaboratory assessment of candidate reference materials for lentiviral vector copy number and integration site measurements.

IF 4.6 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Molecular Therapy-Methods & Clinical Development Pub Date : 2025-04-21 eCollection Date: 2025-06-12 DOI:10.1016/j.omtm.2025.101472
Hua-Jun He, Zhiyong He, Steven P Lund, Laure Turner, Yongjun Fan, Yu Qiu, David C Corney, Boro Dropulic, Rimas Orentas, Oxana Slessareva, Priscilla Welch, Katie Dungca, Ellen Stelloo, Gabrielle Dijksteel, Harma Feitsma, Sana Ahmed-Seghir, Rostyslav Makarenko, Engin Altunlu, Daniëlle Steenmans, Jan Spanholtz, Monica Raimo, Shai Senderovich, Barbara S Paugh, Chieh-Yuan Li, Benjamin Schroeder, Alexandra S Whale, Dilek Yener, Carole A Foy, Shareef Nahas, Feng Tu, Michael Sheldon, Yan Ding, Jennifer Kandell, Uma Lakshmipathy, Jennifer H McDaniel, Justin M Zook, Sierra Miller, Samantha Maragh, Simona Patange, Mahir Mohiuddin, Alessandro Tona, Kenneth D Cole, Sheng Lin-Gibson
{"title":"Interlaboratory assessment of candidate reference materials for lentiviral vector copy number and integration site measurements.","authors":"Hua-Jun He, Zhiyong He, Steven P Lund, Laure Turner, Yongjun Fan, Yu Qiu, David C Corney, Boro Dropulic, Rimas Orentas, Oxana Slessareva, Priscilla Welch, Katie Dungca, Ellen Stelloo, Gabrielle Dijksteel, Harma Feitsma, Sana Ahmed-Seghir, Rostyslav Makarenko, Engin Altunlu, Daniëlle Steenmans, Jan Spanholtz, Monica Raimo, Shai Senderovich, Barbara S Paugh, Chieh-Yuan Li, Benjamin Schroeder, Alexandra S Whale, Dilek Yener, Carole A Foy, Shareef Nahas, Feng Tu, Michael Sheldon, Yan Ding, Jennifer Kandell, Uma Lakshmipathy, Jennifer H McDaniel, Justin M Zook, Sierra Miller, Samantha Maragh, Simona Patange, Mahir Mohiuddin, Alessandro Tona, Kenneth D Cole, Sheng Lin-Gibson","doi":"10.1016/j.omtm.2025.101472","DOIUrl":null,"url":null,"abstract":"<p><p>While lentiviral vectors have played a critical role in the emergence of gene-modified cell therapies, safety concerns remain regarding potential insertional mutagenesis. Regulatory authorities strongly recommend risk assessment and management of vector copy numbers (VCNs), integration profiles, and integration sites in the lentivirus-based cell and gene therapy products. However, accurately measuring these parameters remains a significant challenge due to the lack of standardized methodologies and VCN reference materials (RMs). Toward this challenge, we conducted an interlaboratory study on NIST candidate RMs for VCN measurements. The candidate RMs comprise five human genomic DNA samples or fixed cells from clonal Jurkat cell lines with defined VCNs ranging from 0 to 4. All 12 study participants were able to identify the VCN in the five blinded samples using quantitative PCR (qPCR), digital PCR (dPCR), or next generation sequencing (NGS) assays. Consensus value of VCN and integration sites in these candidate RMs were achieved. The fixed clonal VCN cells were also used to evaluate an emerging imaging-based technology called molecular combing. This interlaboratory assessment demonstrated the utility, commutability, and suitability of the NIST VCN candidate RMs for quality assurance and improved confidence in VCN, integration profile, and integration site measurements.</p>","PeriodicalId":54333,"journal":{"name":"Molecular Therapy-Methods & Clinical Development","volume":"33 2","pages":"101472"},"PeriodicalIF":4.6000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229725/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy-Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2025.101472","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/12 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

While lentiviral vectors have played a critical role in the emergence of gene-modified cell therapies, safety concerns remain regarding potential insertional mutagenesis. Regulatory authorities strongly recommend risk assessment and management of vector copy numbers (VCNs), integration profiles, and integration sites in the lentivirus-based cell and gene therapy products. However, accurately measuring these parameters remains a significant challenge due to the lack of standardized methodologies and VCN reference materials (RMs). Toward this challenge, we conducted an interlaboratory study on NIST candidate RMs for VCN measurements. The candidate RMs comprise five human genomic DNA samples or fixed cells from clonal Jurkat cell lines with defined VCNs ranging from 0 to 4. All 12 study participants were able to identify the VCN in the five blinded samples using quantitative PCR (qPCR), digital PCR (dPCR), or next generation sequencing (NGS) assays. Consensus value of VCN and integration sites in these candidate RMs were achieved. The fixed clonal VCN cells were also used to evaluate an emerging imaging-based technology called molecular combing. This interlaboratory assessment demonstrated the utility, commutability, and suitability of the NIST VCN candidate RMs for quality assurance and improved confidence in VCN, integration profile, and integration site measurements.

慢病毒载体拷贝数和整合位点测量候选参考物质的实验室间评估。
虽然慢病毒载体在基因修饰细胞疗法的出现中发挥了关键作用,但关于潜在插入突变的安全性问题仍然存在。监管当局强烈建议对慢病毒细胞和基因治疗产品中的载体拷贝数(VCNs)、整合谱和整合位点进行风险评估和管理。然而,由于缺乏标准化的方法和VCN参考材料(RMs),准确测量这些参数仍然是一个重大挑战。针对这一挑战,我们对VCN测量的NIST候选均方根进行了实验室间研究。候选RMs包括5个人类基因组DNA样本或克隆Jurkat细胞系的固定细胞,VCNs范围为0至4。所有12名研究参与者都能够通过定量PCR (qPCR)、数字PCR (dPCR)或下一代测序(NGS)检测在5个盲法样本中识别VCN。在这些候选rm中,VCN和整合位点的值是一致的。固定克隆VCN细胞也被用于评估一种新兴的基于成像的技术,称为分子梳理。该实验室间评估展示了NIST VCN候选rm的实用性、可交换性和适用性,用于质量保证和提高VCN、集成概要和集成站点测量的信心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy-Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.90
自引率
4.30%
发文量
163
审稿时长
12 weeks
期刊介绍: The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Topics of particular interest within the journal''s scope include: Gene vector engineering and production, Methods for targeted genome editing and engineering, Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells, Methods for gene and cell vector delivery, Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine, Analysis of gene and cell vector biodistribution and tracking, Pharmacology/toxicology studies of new and next-generation vectors, Methods for cell isolation, engineering, culture, expansion, and transplantation, Cell processing, storage, and banking for therapeutic application, Preclinical and QC/QA assay development, Translational and clinical scale-up and Good Manufacturing procedures and process development, Clinical protocol development, Computational and bioinformatic methods for analysis, modeling, or visualization of biological data, Negotiating the regulatory approval process and obtaining such approval for clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信